English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

MDM2 gene amplification was investigated by the fluorescence in situ hybridization (FISH) method in 40 patients with CLL and 20 patients with Ph+ chronic myeloid leukemia as a control group. Informed consent was received. The modified Rai staging system was used for staging our patients. Conventional cytogenetic analysis and FISH analysis using CLL-specific FISH probes for 17p13.1 (TP53), 13q14 (RB), 6q22-q23 (MYB), 11q22.3 (ATM), and chromosome 12 centromere were applied for all patients. The cytogenetic analysis revealed abnormal karyotypes in 3 of 40 patients. 47,XX,inv(9)(p11q13),del(13)(q14),+21[2],46,XY,del (7) (q31),dup(12)(q21q21)[8], and 46,XY,del(20)(q12)[6] karyotypes were observed in these patients. MDM2 gene amplification could not be detected in either the patient or the control group. FISH analysis results were as follows in CLL cases: deletion of 17p13.1 in 16 cases (40%), 13q14 deletion in 13 cases (32.5%), trisomy 12 in 12 cases (30%), 11q22.3 deletion in 6 cases (15%), and 6q23 deletion in 1 case (2.5%). Frequencies of molecular cytogenetic findings are presented in Figure 1A. Compared to the literature, where the frequency of deletion of 17p13.1 in early-stage CLL was reported between 7% and 10% [7,8], the higher rate observed in 75% of our CLL patients might be due to differences in the methods and probes used, variability of laboratory cut-off values, or the limited number of cases in this study. The clinical implication of having 17p13.1 deletions in CLL cases might be more dependent on the extent of 17p13.1 deletion than the stage of the disease [9]. In the present study, only 4 patients had 17p13.1 deletion in >20 cells. Two of them died because of progressive disease and the other two were lost to follow-up. If evaluated from this perspective, the high level of 17p13.1 deletion was observed in 10% of our cases. It has been observed that patients with 17p13.1 and 11q2.3 deletion have a poor prognosis, and patients with isolated 13q14 deletion were found to have slower progression and longer survival time

Investigation Of Mdm2 Oncogene Copy Number Alterations in Cases With Chronic Lymphocytic Leukemia